GLP-1 Drugs and Muscle Loss: Long-Term Health Risks
GLP-1 Drugs: A Double-Edged Sword for Weight Loss? New Research Raises Concerns About Cardiorespiratory Fitness
Table of Contents
New research from the University of Virginia health System is shedding light on a critical, yet frequently enough overlooked, aspect of GLP-1 drugs: their impact on cardiorespiratory fitness (CRF). while these popular medications are highly effective at reducing body weight and adiposity, a recent review of medical literature suggests they may not enhance, and could potentially even diminish, a key indicator of longevity and overall health.
The Superiority of Cardiorespiratory Fitness
The study’s authors highlight a significant finding from their own prior research: “In a recent study by our group that examined mortality outcomes from almost 400,000 individuals across the world, we found that CRF was far superior to overweight or obesity status for predicting the risk of death. In fact, once CRF was factored in, body weight failed to predict the risk of mortality.” This underscores the profound importance of CRF, ofen measured by VO₂max (maximal oxygen uptake), as a predictor of healthspan and lifespan.
GLP-1 Drugs and VO₂max: A Disconnect
The review of available medical literature revealed a concerning trend. While GLP-1 drugs demonstrably improve certain measures of heart function, these improvements do not appear to translate into significant gains in VO₂max.This disconnect is a primary concern for researchers, who emphasize the need to understand how these drugs affect CRF.
“This is why it’s so vital to understand the effects of this new class of drugs on it,” stated one of the lead researchers.
While some small studies have hinted that exercise might help improve VO₂max in patients taking GLP-1 drugs, the researchers caution that these studies had significant limitations, including poor controls. larger, well-designed studies are urgently needed to validate these preliminary findings.
Ensuring Healthy Weight loss: Preserving Muscle Mass is Key
The researchers’ ultimate conclusion is that GLP-1 drugs “substantially reduce body weight and adiposity, along with a substantial FFM [fat-free mass] loss, but with no clear evidence of CRF enhancement.” This substantial loss of fat-free mass, which includes muscle, is a major concern. The authors worry that this could negatively impact patients’ metabolic health, healthspan, frailty, and overall longevity.
“They are urging additional research to better understand the effects of the drugs and ensure patients get the best possible outcomes,” the report states.
Promising Avenues for Intervention
Despite these concerns, there are promising signs on the horizon. The researchers note that medications are in development that could help mitigate the loss of lean muscle mass. One such promising development is a monoclonal antibody currently in the pipeline that might potentially be able to offset this loss.
“This is an area of active research, and we are hopeful that better solutions are coming soon,” said Dr. Liu, a lead author on the study. “But for now it is important that patients prescribed GLP-1 drugs have conversations with their healthcare providers about strategies to preserve muscle mass.”
Expert Recommendations for Patients
The American Diabetes association recommends proactive measures for patients considering or currently taking GLP-1 medications. These include:
Screening for Malnutrition and Low Muscle Mass Risk: This assessment should occur before initiating treatment.
Promoting Adequate Protein Intake: Ensuring sufficient protein consumption is crucial for muscle maintenance.
Regular Exercise Throughout Treatment: Consistent physical activity is vital for overall health and potentially for preserving muscle mass and CRF.
“” added Dr. Angadi, another lead author, “exercise training during GLP1 therapy remains to be assessed in its ability to preserve or improve VO₂max during GLP1 therapy.” This highlights a critical area for future research.
Findings Published
The researchers have published their extensive findings in The Journal of Clinical Endocrinology & Metabolism. This work was supported by grants from the National Institutes of Health (R01DK124344 and R01DK125330).
Source: University of Virginia health System
Journal Reference:* Liu,Z., et al. (2025). incretin Receptor Agonism,Fat-free Mass,and Cardiorespiratory Fitness: A Narrative Review. The Journal of clinical Endocrinology & Metabolism*.doi.org/10.1210/clinem/dgaf335